TD Asset Management’s SOPHiA GENETICS SOPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-68,753
Closed -$308K 1445
2023
Q2
$308K Hold
68,753
﹤0.01% 1337
2023
Q1
$342K Buy
68,753
+3,800
+6% +$12.3K ﹤0.01% 1324
2022
Q4
$134K Hold
64,953
﹤0.01% 1406
2022
Q3
$171K Sell
64,953
-26,232
-29% -$91.9K ﹤0.01% 1410
2022
Q2
$330K Sell
91,185
-32,633
-26% -$166K ﹤0.01% 1347
2022
Q1
$957K Sell
123,818
-12,644
-9% -$142K ﹤0.01% 1240
2021
Q4
$1.92M Buy
136,462
+19,308
+16% +$285K ﹤0.01% 1142
2021
Q3
$2.05M Buy
+117,154
New +$2.06M ﹤0.01% 1079

Other funds holding SOPH

TD Asset Management's SOPH Position: Q3 2023 in Review

TD Asset Management sold out of SOPHiA GENETICS (SOPH) in Q3 2023, closing a stake of 68,753 shares — an estimated $308K sold.

TD Asset Management first reported a position in SOPH in Q3 2021 and held it in 8 quarters. The position peaked at $2.05M in Q3 2021. 32 funds tracked by Wall St. Rank hold SOPH as of Q3 2023.

  • TD Asset Management reported no remaining SOPHiA GENETICS position as of Q3 2023 after selling out during the quarter.
  • TD Asset Management sold 68,753 SOPHiA GENETICS shares in Q3 2023, an estimated $308K.
  • TD Asset Management first reported a position in SOPHiA GENETICS in Q3 2021 and held it in 8 quarters.
  • TD Asset Management's SOPHiA GENETICS position peaked at $2.05M in Q3 2021.
  • 32 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q3 2023.

Based on TD Asset Management's 13F filing for Q3 2023, filed 27 Oct 2023.